Table of Contents
Clinicians Will Likely Opt for Integrated Analyzers over Standalone Clinical and Immunoassay Analyzers in the Next 2 Years
This study provides trends in the US immunochemistry market and the clinical chemistry market. The install base of analyzer models from top vendors are projected from 2012 and 2013, and resulting trends have been studied. The study includes list prices of analyzers, analytes detected, and average discounts offered. Customer segmentation includes various analyzers from vendors such as Abbott Diagnostics, Siemens Healthcare, Roche Diagnostics, Phadia (Thermo Fisher Scientific), Alere, Inova Diagnostics, Tosoh Bioscience, bioMérieux, DiaSorin, Bio-Rad, IDS, Ortho-Clinical Diagnostics, Awareness Technology, The Binding Site, and Beckman Coulter.
Executive Summary—Key Findings
-The US immunochemistry market generated $ million in 2013 and is expected to grow at a compound annual growth rate (CAGR) of% from 2013 to 2015. The market comprises the sales of analyzers and reagents. The US immunochemistry market represents % of the US in vitro diagnostics (IVD) market.
-The immunochemistry market is heavily impacted by rapid replacement trends, which affect the clinical chemistry market. The clinical chemistry market contributed % of the US IVD market. The US clinical chemistry market generated $ million in 2013 and is expected to grow at a CAGR of % from 2013 to 2015.
-In terms of technology trends, the market is increasingly seeing the entry of chemiluminescence immunoassay (CLIA) systems, which are replacing older versions. Smaller labs still opt for fluorescent immunoassay (FIA) systems or semi-automated CLIA systems. Enzyme-linked immunosorbent assay (ELISA) systems and open systems are exhibiting some growth because of their open platform capabilities and larger test menu and affordability. FIA and CLIA systems tend to be more expensive. which works in favor of ELISA systems.
-Frost & Sullivan, however, estimates that ELISA systems will eventually experience erosion because of their lack of sensitivity and low specificities, especially as most laboratories are now consolidating and converting to high throughput systems. As a result, many vendors are using this opportunity to offer immunoassay or standalone clinical chemistry systems for a high discounted price. Demand for immunochemistry systems seems to work negatively for vendors. Because of this, the retention of the install base is crucial. Some strategies adopted by vendors include offering large discounts/upgrades, adding automation capabilities to existing modules, and having long reagent rental contracts.
-Frost & Sullivan’s install base analysis reveals that a few open system platforms are declining in their install base, leading to rapid transition to either an FIA or a CLIA system.
-Dominating vendors are Roche Diagnostics, Siemens Healthcare Diagnostics, and Abbott Diagnostics. The US immunochemistry market is seeing the influx of many newer companies from Canada, Japan, China, and Europe. The market has undergone a massive change from a handful of participants offering only ELISA, CLIA, radioimmunoassay (RIA), and FIA as well as multiparametric assays such as microarrays, flow cytometry-based platforms, recombinant immunoassays, and indirect immunofluorescence assays (IFA).
Get Industry Insights. Simply.
Talk to Ahmad
+1 718 618 4302
This new 75-country survey from VPGMarketResearch.com provides granular data and analysis not available from any other published source. The survey is designed to help current suppliers and potential market ...
This new report from VPGMarketResearch.com provides granular analysis of the Europe diagnostic testing market, including Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, ...
This new report from VPGMarketResearch.com provides granular analysis of the Asia-Pacific diagnostic testing market, including Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, ...